Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
RANO
breast cancer
leptomeningeal metastases
radiological assessment
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
revised:
23
03
2023
received:
14
10
2022
accepted:
21
04
2023
medline:
21
7
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
ppublish
Résumé
Assessment of treatment response in patients (pts) with leptomeningeal metastases (LM) represents a significant challenge and standardized criteria are needed. In 2017, the RANO LM Working Group proposed a standardized scorecard to evaluate MRI findings (further simplified in 2019). Here, we aim to validate the prognostic impact of response to treatment assessed using this tool in a multicentric cohort of breast cancer (BC) pts. Pts with BC-related LM diagnosed at two institutions between 2005 and 2018 were identified. Baseline and follow-up MRI scans were centrally reviewed and response assessment was evaluated using 2019 revised RANO LM criteria. A total of 142 pts with BC-related LM and available baseline brain MRI imaging were identified; 60 of them had at least one follow-up MRI. In this subgroup, median overall survival (OS) was 15.2 months (95%CI 9.5-21.0). At first re-evaluation, radiological response by RANO criteria was: complete response (CR) in 2 pts (3%), partial response (PR) in 12 (20%), stable disease (SD) in 33 (55%) and progression of disease (PD) in 13 (22%). Median OS was 31.1 months (HR 0.10, 95%CI 0.01-0.78) in pts with CR, 16.1 months (HR 0.41, 95%CI 0.17-0.97) in pts with PR, 17.9 months (HR 0.45, 95%CI 0.22-0.91) in pts with SD and 9.5 months in pts with PD (P = .029). A second blinded evaluation showed a moderate interobserver agreement (K = 0.562). Radiological response according to 2019 RANO criteria is significantly associated with OS in pts with BC-related LM, thus supporting the use of this evaluation tool both in trials and clinical practice.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1217-1226Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103-119. doi:10.1053/ctrv.1999.0119
le Rhun E, Weller M, Brandsma D, et al. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28:iv84-iv99. doi:10.1093/annonc/mdx221
Griguolo G, Pouderoux S, Dieci MV, et al. Clinicopathological and treatment-associated prognostic factors in patients with breast cancer leptomeningeal metastases in relation to tumor biology. Oncologist. 2018;23:1289-1299. doi:10.1634/theoncologist.2018-0200
Chamberlain M, Junck L, Brandsma D, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2017;19:484-492. doi:10.1093/neuonc/now183
le Rhun E, Devos P, Boulanger T, et al. The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol. 2019;21:648-658. doi:10.1093/neuonc/noz024
Naidoo J, Schreck KC, Fu W, et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer. 2021;9:9. doi:10.1136/jitc-2021-002473
Wolff AC, Elizabeth Hale Hammond M, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105-2122. doi:10.1200/JCO.2018.77.8738
Murthy RK, O'Brien B, Berry DA, et al. Abstract PD4-02: safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: results from TBCRC049, a phase 2 non-randomized study. Cancer Res. 2022;82:PD4-02. doi:10.1158/1538-7445.sabcs21-pd4-02
Bonneau C, Paintaud G, Trédan O, et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer. 2018;95:75-84. doi:10.1016/j.ejca.2018.02.032
Le Rhun E, Devos P, Winklhofer S, et al. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol. 2022;24:1726-1735. doi:10.1093/neuonc/noac043
Lukas RV. Leptomeningeal metastases-what outcomes should we measure and how? Neuro Oncol. 2022;24:1736-1737. doi:10.1093/neuonc/noac101
Ratosa I, Dobnikar N, Bottosso M, et al. Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort. Int J Cancer. 2022;151:1355-1366. doi:10.1002/ijc.34135
le Rhun E, Devos P, Weller J, et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol. 2021;23:1100-1112. doi:10.1093/neuonc/noaa298
Carausu M, Carton M, Darlix A, et al. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open. 2021;6:100150. doi:10.1016/j.esmoop.2021.100150
Le Rhun E, Taillibert S, Zairi F, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol. 2013;113:83-92. doi:10.1007/s11060-013-1092-8
Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 2013;30:408. doi:10.1007/s12032-012-0408-4
Torrejón D, Oliveira M, Cortes J, et al. Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast. 2013;22:19-23. doi:10.1016/j.breast.2012.10.009
Morikawa A, Jordan L, Rozner R, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17:23-28. doi:10.1016/j.clbc.2016.07.002
Jo J-C, Kang MJ, Kim JE, et al. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. Cancer Chemother Pharmacol. 2013;72:201-207. doi:10.1007/s00280-013-2185-y
Abouharb S, Ensor J, Loghin ME, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014;146:477-486. doi:10.1007/s10549-014-3054-z
Fernandes L, de Matos LV, Cardoso D, et al. Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review. CNS Oncologia. 2020;9:CNS65. doi:10.2217/cns-2020-0023